The potential role of sunitinib in gastrointestinal cancers other than GIST

Critical Reviews in Oncology/hematology
Cristina GrávalosJoan Manel Gasent

Abstract

Gastrointestinal tumors are the most frequent and lethal malignancies worldwide. The deeper knowledge in molecular biology mechanisms involved in carcinogenesis has allowed the design of new targeted drugs mainly directed against the epidermal growth factor receptor (EGFR), the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Sunitinib is an oral multitargeted inhibitor of the VEGF, platelet-derived growth factor (PDGF), and c-KIT, among others, tyrosine kinase receptors. Therefore, sunitinib acts in a dual mode as antiangiogenic agent and as antitumoral drug. The aim of this review is to gather the preclinical rationale behind the clinical use of sunitinib in gastrointestinal malignancies other than gastrointestinal stromal tumors (GIST) and to summarize the clinical data from phase I to III trials currently available.

References

Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold F Dvorak
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gennaro GaliziaCarlo Pignatelli
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pasquina MarzolaFrancesco Osculati
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Jan 25, 2007·Expert Opinion on Investigational Drugs·Jonathan R Strosberg, Larry K Kvols
Feb 3, 2007·Biochemical Pharmacology·Alexander HuetherHans Scherübl
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M Chow, S Gail Eckhardt
May 12, 2007·European Urology·Paul C M S Verhagen
Sep 27, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H IzzedineO Rixe
Jul 21, 2007·The Journal of Clinical Investigation·Marya F McCartyLee M Ellis
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzHeinz J Lenz
Mar 21, 2008·Expert Opinion on Biological Therapy·Eyad ElkordPeter L Stern
Jun 3, 2008·International Journal of Radiation Oncology, Biology, Physics·Kyle C CuneoAnuradha Bapsi Chakravarthy
Jul 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew X ZhuRakesh K Jain
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott KopetzRobert R McWilliams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.